Abstract: The present invention provides breast cancer chemopreventive arylamide analogues of retinoic acid, more particularly C-glycoside analogues of N-(4-hydroxyphenyl)retinamide-O-glucuronide that resist both .beta.-glucuronidase mediated enzymatic hydrolysis as well as acid catalyzed hydrolysis. Specifically, the drugs include 4-(retinamido)phenyl-C-glucuronide; 4-(retinamido)phenyl-C-glucoside; 4-(retinamido)benzyl-C-xyloside; 4-(retinamido)benzyl-C-glucoside; 4-(retinamido)benzyl-C-glucuronide; and 4-(retinamido)phenyl-C-xyloside.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
September 2, 1997
Assignee:
The Ohio State Research Foundation
Inventors:
Robert W. Curley, Jr., Michael J. Panigot
Abstract: The present invention provides breast cancer chemopreventive arylamide analogues of retinoic acid, more particularly C-glycoside analogues of N-(4-hydroxyphenyl)retinamide-O-glucuronide and N-glycoside analogue of retinoyl .beta.-glucuronide that resist both .beta.-glucuronidase mediated enzymatic hydrolysis as well as acid catalyzed hydrolysis. Specifically, the drugs include 4-(retinamido)phenyl-C-glucuronide; 4-(retinamido)phenyl-C-glucoside; 4-(retinamido)benzyl-C-xyloside; 4-(retinamido)benzyl-C-glucoside; 4-(retinamido)benzyl-C-glucuronide; 4-(retinamido)phenyl-C-xyloside, 1-(B-D-glucopyranosyl) retinamide and 1-(D-glucopyranosyluronosly) retinamide. The invention also relates to a method for making such drugs.
Type:
Grant
Filed:
May 26, 1995
Date of Patent:
February 4, 1997
Assignee:
The Ohio State Research Foundation
Inventors:
Robert W. Curley, Jr., Michael J. Robarge
Abstract: The present invention provides breast cancer chemopreventive arylamide analogues of retinoic acid, more particularly C-glycoside analogues of N-(4-hydroxyphenyl)retinamide-O-glucuronide that resist both .beta.-glucuronidase mediated enzymatic hydrolysis as well as acid catalyzed hydrolysis. Specifically, the drugs include 4-(retinamido)phenyl-C-glucuronide; 4-(retinamido)phenyl-C-glucoside; 4-(retinamido)benzyl-C-xyloside; 4-(retinamido)benzyl-C-glucoside; 4-(retinamido)benzyl-C-glucuronide; and 4-(retinamido)phenyl-C-xyloside.
Type:
Grant
Filed:
October 7, 1994
Date of Patent:
November 12, 1996
Assignee:
The Ohio State Research Foundation
Inventors:
Robert W. Curley, Jr., Michael J. Panigot
Abstract: The present invention provides breast cancer chemopreventive arylamide analogues of retinoic acid, more particularly C-glycoside analogues of N-(4-hydroxyphenyl)retinamide-O-glucuronide and N-glycoside analogue of retinoyl .beta.-glucuronide that resist both .beta.-glucuronidase mediated enzymatic hydrolysis as well as acid catalyzed hydrolysis. Specifically, the drugs include 4-(retinamido)phenyl-C-glucuronide; 4-(retinamido)phenyl-C-glucoside; 4-(retinamido)benzyl-C-xyloside; 4-(retinamido)benzyl-C-glucoside; 4-(retinamido)benzyl-C-glucuronide; 4-(retinamido)phenyl-C-xyloside, 1-(B-D-glucopyranosyl) retinamide and 1-(D-glucopyranosyluronosly) retinamide. The invention also relates to a method for making such drugs.
Type:
Grant
Filed:
September 30, 1994
Date of Patent:
May 14, 1996
Assignee:
Ohio State Research Foundation
Inventors:
Robert W. Curley, Jr., Michael J. Robarge
Abstract: A pure bacterial culture, designated herein as M91-3, has been isolated which rapidly degrades certain s-triazines, particularly halogenated s-triazines. The M91-3 degrades s-triazines, particularly atrazine, beyond the point of ring cleavage, leading to complete mineralization of the atrazine. The ability of M91-3 to completely degrade atrazine appears to be unique among bacteria. The M91-3 is capable of degrading s-triazine in solution and in presence of soil or sediment. The invention also relates to a method for degrading s-triazines, particularly atrazine.
Type:
Grant
Filed:
February 22, 1994
Date of Patent:
July 4, 1995
Assignee:
Ohio State Research Foundation
Inventors:
Mark Radosevich, Olli H. Tuovinen, Samuel J. Traina
Abstract: Anthracycline antibiotics represented by the formula (I) ##STR1## wherein R is hydrogen or hydroxyl, one of X and Y is fluorine and the other is hydrogen or both X and Y are fluorine, and S is a 2-halo sugar moiety; pharmaceutical preparations containing the same; and a method for inhibiting the growth of mammalian tumors are disclosed.
Type:
Grant
Filed:
March 20, 1985
Date of Patent:
May 5, 1987
Assignee:
The Ohio State Research Foundation
Inventors:
John S. Swenton, Derek Horton, Waldemar Priebe, Gary W. Morrow